(Q37965625)

26 August 2017

title

Experiences with adverse drug reaction reporting by patients: an 11-country survey (English)

1 reference

26 August 2017

0 references

Florence van Hunsel

1

1 reference

26 August 2017

Linda Härmark

2

1 reference

26 August 2017

Shanthi Pal

3

1 reference

26 August 2017

Sten Olsson

4

1 reference

26 August 2017

Kees van Grootheest

5

1 reference

26 August 2017

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

35

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

45-60

1 reference

Patients' role in reporting adverse drug reactions

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Adverse drug reaction reporting by patients in the Netherlands: three years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

The medical dictionary for regulatory activities (MedDRA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Motives for reporting adverse drug reactions by patient-reporters in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Effect of consumer reporting on signal detection: using disproportionality analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Community pharmacists' views on adverse drug reactions reporting in Malaysia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Social media and networks in pharmacovigilance: boon or bane?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Using Facebook to increase spontaneous reporting of adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

"Serious" and "severe" adverse drug reactions need defining

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

What motivates patients to report an adverse drug reaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594320-000000000-00000

Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.

21 January 2018

1 reference

12 December 2020

[Direct reporting of side effects by the patient: favourable experience in the first year]

1 reference

12 December 2020

Improving pharmacovigilance in Europe

1 reference

12 December 2020

A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.

1 reference

12 December 2020

Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain.

1 reference

12 December 2020

New rules will allow EU patients to report drug concerns directly

1 reference

12 December 2020

Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme

1 reference

12 December 2020

The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective

1 reference

12 December 2020

10.2165/11594320-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1029270718

0 references

1 reference